Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase I/IIa study investigating inhaled CIS-DPI as add-on treatment in Stage IV NSCLC patients
2022-501183-17-00Phase 2Completed
- Sponsor
- InhaTarget Therapeutics
- Start
- Dec 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
- Countries
- 3
01
Overview
Phase 2 trial of CIS-DPI in non-small cell lung cancer (NSCLC), sponsored by InhaTarget Therapeutics. Started Dec 2022; status: completed.
02
Drugs
CIS-DPI
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2022-501183-17-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-501183-17-00.